Laurence Baudrin

1.3k total citations
15 papers, 285 citations indexed

About

Laurence Baudrin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Laurence Baudrin has authored 15 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 3 papers in Surgery. Recurrent topics in Laurence Baudrin's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Research Studies (5 papers). Laurence Baudrin is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Research Studies (5 papers). Laurence Baudrin collaborates with scholars based in France. Laurence Baudrin's co-authors include B. Milleron, Jacques Cadranel, Marie Wislez, A. Lavolé, Marie-Paule Lebitasy, Élisabeth Quoix, Gérard Zalcman, Martine Antoine, Franck Morin and Virginie Poulot and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology and Lung Cancer.

In The Last Decade

Laurence Baudrin

15 papers receiving 276 citations

Peers

Countries citing papers authored by Laurence Baudrin

Since Specialization

Citations

This map shows the geographic impact of Laurence Baudrin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Baudrin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Baudrin more than expected).

Fields of papers citing papers by Laurence Baudrin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Baudrin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Baudrin. The network helps show where Laurence Baudrin may publish in the future.

Co-authorship network of co-authors of Laurence Baudrin

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence Baudrin. A scholar is included among the top collaborators of Laurence Baudrin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence Baudrin. Laurence Baudrin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	A DNA-repair prognostic signature for early-stage NSCLC patients, in IFCT-0002 trial of neoadjuvant chemotherapy. 2013 ·Journal of Clinical Oncology ·Gérard Zalcman, Guénaëlle Levallet, Pierre Fouret, Martine Antoine, Élisabeth Brambilla, Emmanuel Bergot, Françoise Galateau-Sallé, A. Lavolé, Élisabeth Quoix, D. Debieuvre, Julien Mazières, Denis Moro‐Sibilot, Jean-Louis Pujol, Denis Braun, Michèle Beau‐Faller, Laurence Baudrin, Franck Morin, Virginie Westeel, (unknown)	2
2	Comparison of two chemotherapy regimens in non-small cell lung cancer patients relapsing after surgery and peri-operative chemotherapy (IFCT-0702 study). 2013 ·Journal of Clinical Oncology ·Denis Moro‐Sibilot, Clarisse Audigier-Valette, P. Merle, Élisabeth Quoix, Pierre Jean Souquet, Fabrice Barlési, C. Chouaïd, O. Molinier, A. Lavolé, Julien Mazières, Laurence Baudrin, Franck Morin, Gérard Zalcman, (unknown)	1
3	Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup. 2013 ·Journal of Clinical Oncology ·Jean‐Charles Soria, Fabrice Barlési, Benjamin Besse, Julien Mazières, P. Merle, Jacquès Cadranel, Clarisse Audigier-Valette, Denis Moro‐Sibilot, (unknown), François Goupil, Patrick Renault, Élisabeth Quoix, Pierre Jean Souquet, Anne Madroszyk, R. Corre, David Pérol, Laurence Baudrin, Franck Morin, Gérard Zalcman, Marie Wislez, (unknown)	7
4	Concurrent Chemoradiation for Elderly Patients with Locally Advanced Non-Small-Cell Lung Cancer: Still a Controversial Issue 2012 ·Aging Health ·Virginie Westeel, Élisabeth Quoix, Laurence Baudrin, B. Milleron	2
5	Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic 2012 ·Bulletin du Cancer ·A. Lavolé, (unknown), Laurence Baudrin, V. Gounant, Anne-Marie Ruppert, (unknown), L. Belmont, (unknown), J. Cadranel, B. Milleron	21
6	Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial 2012 ·Journal of Thoracic Oncology ·M. Duruisseaux, Laurence Baudrin, Élisabeth Quoix, Marie Wislez, Denis Moro‐Sibilot, D. Coëtmeur, I. Monnet, Pierre Mourlanette, Jean‐François Morère, Jean‐Charles Soria, Virginie Westeel, Franck Morin, Jacques Cadranel	5
7	Protocole IFCT 0803 – Étude de phase II évaluant l’association de cétuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pémétrexed dans le traitement des cancers bronchiques non à petites cellules non épidermoïdes de stade III, inopérables 2011 ·Revue des Maladies Respiratoires ·Jean Trédaniel, F. Mornex, I. Barillot, (unknown), Christophe Hennequin, C. Le Péchoux, A. Lavolé, P. Giraud, P.-J. Souquet, Luís Teixeira, F. Vaylet, Gérard Zalcman, Laurence Baudrin, Franck Morin, B. Milleron	4
8	Use of a three-microRNA signature to discriminate prognostic groups in early-stage NSCLC patients in the IFCT-0002 trial. 2011 ·Journal of Clinical Oncology ·Céline Mascaux, Guénaëlle Levallet, Emmanuel Bergot, Laurence Baudrin, (unknown), G. Anthoine, V. Westeel, A. Lavolé, Élisabeth Quoix, D. Debieuvre, Julien Mazières, J.L. Pujol, Denis Moro‐Sibilot, (unknown), B. Milleron, Gérard Zalcman, (unknown)	2
9	IFCT-0504 trial: Mucinous (M) and nonmucinous (NM) cytologic subtypes interaction effect in first-line treatment of advanced bronchioloalveolar carcinoma (BAC) by erlotinib (E) or carboplatin/paclitaxel (C/P). 2011 ·Journal of Clinical Oncology ·Jacques Cadranel, R. Gervais, Marie Wislez, P. Merle, Denis Moro‐Sibilot, V. Westeel, L. Bigay-Gamé, Élisabeth Quoix, S. Friard, Fabrice Barlési, (unknown), L. Moreau, Isabelle Monnet, (unknown), G. Oliviéro, P.-J. Souquet, Luc Thiberville, Laurence Baudrin, (unknown), Gérard Zalcman, (unknown)	1
10	Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study) 2010 ·Lung Cancer ·Jean‐François Morère, J.-M. Bréchot, Virginie Westeel, V. Gounant, B Lebeau, F. Vaylet, Fabrice Barlési, T. Urban, Pierre-Jean Souquet, D. Debieuvre, Laurence Baudrin, Gérard Zalcman, Franck Morin, B. Milleron, Denis Moro‐Sibilot	32
11	Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). 2010 ·Journal of Clinical Oncology ·Élisabeth Quoix, (unknown), V. Westeel, Éric Pichon, Gérard Zalcman, Laurence Baudrin, A. Lavolé, Jérôme Dauba, Marie-Paule Lebitasy, B. Milleron, (unknown)	46
12	Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib 2009 ·Lung Cancer ·Marie Wislez, Martine Antoine, Laurence Baudrin, Virginie Poulot, Agnès Neuville, (unknown), Élisabeth Longchampt, (unknown), Marie-Paule Lebitasy, Jacques Cadranel	70
13	IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype 2009 ·Journal of Thoracic Oncology ·J. Cadranel, Élisabeth Quoix, Laurence Baudrin, Pierre Mourlanette, Denis Moro‐Sibilot, Jean‐François Morère, Pierre-Jean Souquet, Jean‐Charles Soria, Franck Morin, B. Milleron	41
14	Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer 2009 ·Lung Cancer ·A. Lavolé, C. Chouaïd, Laurence Baudrin, Marie Wislez, G Raguin, Gilles Pialoux, Pierre‐Marie Girard, B. Milleron, Jacques Cadranel	49
15	IFCT0401-bio phase II trial: Gefitinib administered as 1st-line in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC)—Predictive biomarkers of efficacy and survival 2008 ·Journal of Clinical Oncology ·Marie Wislez, (unknown), Virginie Poulot, Laurence Baudrin, Michèle Beau‐Faller, Jean‐François Morère, E Brambilla, Marie-Paule Lebitasy, Florence Coulet, Jacques Cadranel	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact